- Global Pharma News & Resources

CO.DON AG: Restructuring program implemented

DGAP-News: CO.DON AG / Key word(s): Miscellaneous
18.03.2020 / 11:00
The issuer is solely responsible for the content of this announcement.

CO.DON AG: Restructuring program implemented

Berlin / Teltow / Leipzig, March 18th, 2020 - CO.DON AG has implemented a comprehensive restructuring within the scope of an analysis of all internal structures and business processes and has thus taken measures for long-term economic security.

Core aspects are the concentration on the reduction of the monthly consumption of financial resources by streamlining the organisational structures and internal processes as well as the focus of all departments on a significant and sustainable increase in sales in Germany and the European target markets that have been developed or are being developed. Among other things, in-house research and active acquisition in the area of contract production and activities relating to market entry efforts in non-European markets were reduced in terms of resources until break-even will be reached.

Tilmann Bur, CEO of CO.DON AG: "Realism, perspective and finally profitability - these are the cornerstones of the realignment of CO.DON AG. We are one of the world's leading manufacturers of cell transplants and have an EU-wide approved product. Our production facility offers one of the world's most advanced technologies for the cultivation of human cells. We can be quite rightly proud of this. In the course of the necessary restructuring, we have now set the solid foundation for a future strategy of our company".

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 15,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). At the Leipzig site, CO.DON has built one of the world's largest and most modern facilities for the production of human cells on an industrial scale for in-house and contract manufacturing. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Tilmann Bur.

Further information is available from



Matthias Meißner
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)30-240352330
F: +49 (0)30-240352309

18.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Phone: 03328 43460
Fax: 03328 434643
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1000373

End of News DGAP News Service

Editor Details

Last Updated: 18-Mar-2020